Internal Medicine, Hematology & Oncology · Bolingbrook, IL
NPI
1477971216
Since 2014
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
420 N Schmidt Rd Ste 230
Bolingbrook, IL, 60440
Phone (630) 312-2000
Groups this clinician bills Medicare through
Medicare paid, 2024
$46K
701 services
Medicare patients, 2024
247
Average age 75
Drug cost, 2024
$1.6M
761 prescriptions
Company payments, 2025
$129
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Keerthi Tamragouri was code 99214 (office e&m - established), 148 times for 63 patients. In total Keerthi Tamragouri billed 701 services in 11 codes, and Medicare paid $46K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-09-02.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 148 | 63 | $74.25 | $11K |
| 99214 Office E&M - Established | Facility | 100 | 46 | $75.18 | $7,518 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 81 | 50 | $13.38 | $1,084 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 80 | 54 | $13.38 | $1,070 |
| 99232 Hospital E&M - Subsequent | Facility | 56 | 37 | $64.24 | $3,597 |
| 99223 Hospital E&M - Initial | Facility | 50 | 47 | $138.13 | $6,906 |
| 99213 Office E&M - Established | Facility | 46 | 35 | $43.93 | $2,021 |
| 99213 Office E&M - Established | Office | 44 | 33 | $50.00 | $2,200 |
| 99205 Office E&M - New | Office | 19 | 19 | $143.09 | $2,719 |
| 99205 Office E&M - New | Facility | 19 | 19 | $133.14 | $2,530 |
| 99204 Office E&M - New | Facility | 16 | 16 | $102.30 | $1,637 |
By year: 2022 $42K for 497 services; 2023 $34K for 395 services; 2024 $46K for 701 services.
Medicare prescription drug claims, 2024
In 2024, the drug Keerthi Tamragouri prescribed most often to Medicare patients was Eliquis (Apixaban), with 128 prescriptions and refills. In total Keerthi Tamragouri wrote 761 Medicare prescriptions that cost $1.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 128 | 178 | 27 | $102K |
| Anastrozole Generic | 113 | 194 | 24 | $1,417 |
| Hydroxyurea Generic | 38 | 58 | Under 11 | $532 |
| Acyclovir Generic | 34 | 34 | Under 11 | $459 |
| Xarelto Rivaroxaban | 32 | 40 | Under 11 | $22K |
| Tamoxifen Citrate Generic | 24 | 52 | Under 11 | $495 |
| Prochlorperazine Maleate Generic | 23 | 23 | 18 | $207 |
| Ondansetron Hcl Generic | 22 | 22 | 19 | $118 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 21 | 21 | Under 11 | $33.73 |
| Exemestane Generic | 20 | 41 | Under 11 | $6,054 |
| Revlimid Lenalidomide | 20 | 20 | Under 11 | $360K |
| Gabapentin Generic | 17 | 17 | Under 11 | $59.27 |
| Pemazyre Pemigatinib | 16 | 16 | Under 11 | $268K |
| Venclexta Venetoclax | 16 | 16 | Under 11 | $76K |
| Letrozole Generic | 12 | 33 | Under 11 | $299 |
Brand drugs: 285 claims; generic drugs: 476 claims; opioid claims: 17.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Keerthi Tamragouri $129 ($129 in general payments such as food, travel and fees) from 5 companies. The largest payer was Novartis Pharmaceuticals Corporation with $44.66.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.